Rockwell Medical Technologies, Inc. (NASDAQ: RMTI) rated to Underweight with price target $7 by Morgan Stanley
Morgan Stanley rated Rockwell Medical
Technologies, Inc. (NASDAQ: RMTI) to Underweight with price target $7.
Rockwell Medical Technologies, Inc.
manufactures, sells and distributes hemodialysis concentrate solutions and dialysis kits. The Company sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Latin America, Asia and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). Hemodialysis concentrates comprises two primary product types, which are described as acidified dialysate concentrate, also known as acid concentrate, and bicarbonate. The Company?s dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient?s bloodstream. Rockwell Medical Technologies, Inc.
has licensed and is developing renal drug therapies for both iron-delivery and carnitine/vitamin-delivery, utilizing dialysate as the delivery mechanism.
Investment Research is one of the financial industry's dominant thought leaders in equity and fixed-income investing. Our analysts, economists, and strategists have earned this reputation through timely, in-depth analysis of companies, industries, markets, and the world’s economies. Our teams collaborate to assist Morgan Stanley
clients with investment decisions, using cash and derivative instruments across major asset classes and geographies.